Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-14

Clinical Trial Update: Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of silmitasertib (CX-4945) in patients with severe COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Silmitasertib (CX-4945) (silmitasertib)

Snippet

Sponsor: University of Arizona | Conditions: Coronavirus | Phase 2 | Status: TERMINATED | Results posted: 2023-08-14